Skip to main content

Advertisement

SpringerLink
Log in

Neuronal pentraxin II (NPTX2) Is Frequently Down-Regulated by Promoter Hypermethylation in Pancreatic Cancers

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Gene silencing via promoter hypermethylation plays a crucial role in the pathogenesis of cancers. Neuronal pentraxin II (NPTX2) has been observed to be hypermethylated in pancreatic cancers. Methylation of NPTX2 might provide a novel diagnostic marker for pancreatic cancers.

Aim

The objective of this study is to investigate the abnormal patterns of DNA methylation of NPTX2 in pancreatic cancers, and its role in the transcriptional silencing of NPTX2.

Methods

NPTX2 expression was detected by reverse-transcription polymerase chain reaction (RT-PCR), and the methylation status of NPTX2 was assessed by methylation-specific polymerase chain reaction (MSP). Immunohistochemistry was used to examine the NPTX2 protein expression. The pancreatic cancer cell lines were treated with the DNA methyltransferase inhibitor, histone deacetylase inhibitors, either alone or in combination.

Results

The MSP analysis revealed that the promoter region of NPTX2 gene was largely unmethylated in normal pancreatic tissues, while NPTX2 was frequently hypermethylated in pancreatic cancer cells and in primary pancreatic carcinomas. Quantitative RT-PCR revealed that the mean mRNA expression level of NPTX2 in the pancreatic cancer tissues was significantly lower than that in the paired adjacent normal tissues (0.96 ± 0.91 vs. 2.78 ± 1.42, P < 0.001). Consistent with RT-PCR detection, treatment with 5Aza-dC resulted in different degrees of induction of NPTX2 protein in the various cancer cell lines.

Conclusion

We demonstrate that the NPTX2 protein is down-regulated in human primary pancreatic cancers and in pancreatic cancer cell lines. This study provides the first evidence that the down-regulation of NPTX2 tightly correlates with its promoter hypermethylation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science. 2001;293:1068–1070.

    Article  CAS  PubMed  Google Scholar 

  2. Sved J, Bird A. The expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model. Proc Natl Acad Sci USA. 1990;87:4692–4696.

    Article  CAS  PubMed  Google Scholar 

  3. Bonfils C, Beaulieu N, Chan E, Cotton-Montpetit J, MacLeod AR. Characterization of the human DNA methyltransferase splice variant Dnmt1b. J Bio Chem. 2000;275:10754–10760.

    Article  CAS  Google Scholar 

  4. Maiumder S, Ghoshal K, Datta J, Smith DS, Bai S, Jacob ST. Ribosomal RNA gene transcription role of DNA methyltransferases in regulation of human. J Bio Chem. 2006;281:22062–22072.

    Article  Google Scholar 

  5. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7:536–540.

    Article  CAS  PubMed  Google Scholar 

  6. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3:253–266.

    Article  CAS  PubMed  Google Scholar 

  7. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 2002;21:5496–5503.

    Article  CAS  PubMed  Google Scholar 

  8. Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res. 2006;66:1208–1217.

    Article  CAS  PubMed  Google Scholar 

  9. Sato N, Parker AR, Fukushima N, et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene. 2005;24:850–858.

    Article  CAS  PubMed  Google Scholar 

  10. Komazaki T, Nagai H, Emi M, et al. Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol. 2004;34:191–194.

    Article  PubMed  Google Scholar 

  11. Ota N, Kawakami K, Okuda T, et al. Prognostic significance of p16 (INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis. Anticancer Res. 2006;26:3729–3732.

    CAS  PubMed  Google Scholar 

  12. Jeong DH, Youm MY, Kim YN, et al. Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int J Gynecol Cancer. 2006;16:1234–1240.

    Article  CAS  PubMed  Google Scholar 

  13. Attri J, Srinivasan R, Majumdar S, Radotra BD, Wig J. Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. BMC Gastroenterol. 2005;5:22.

    Article  PubMed  Google Scholar 

  14. Ling ZQ, Li P, Ge MH, et al. Aberrant methylation of different DNA repair genes demonstrates distinct prognostic value for esophageal cancer. Dig Dis Sci. 2011;56:2992–3004.

    Article  CAS  PubMed  Google Scholar 

  15. Guo XQ, Wang SJ, Zhang LW, Wang XL, Zhang JH, Guo W. DNA methylation and loss of protein expression in esophageal squamous cell carcinogenesis of high-risk area. J Exp Clin Cancer Res. 2007;26:587–594.

    CAS  PubMed  Google Scholar 

  16. Zhang L, Gao J, Li L, Li Z, Du Y, Gong Y. The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro. Mol Biol Rep. 2011;38:4903–4911.

    Article  CAS  PubMed  Google Scholar 

  17. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003;63:3735–3742.

    CAS  PubMed  Google Scholar 

  18. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28:E32.

    Article  CAS  PubMed  Google Scholar 

  19. Meehan RR, Stancheva I. DNA methylation and control of gene expression in vertebrate development. Essays Biochem. 2001;37:59–70.

    CAS  PubMed  Google Scholar 

  20. de Maat MF, van de Velde CJ, Umetani N, et al. Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol. 2007;25:4887–4894.

    Article  PubMed  Google Scholar 

  21. Sato N, Fukushima N, Chang R, Matsubayashi H, Goggins M. Differential and epigenetic gene expression profiling identifies frequent distribution of the RELN pathway in pancreatic cancers. Gastroenterology. 2006;130:548–565.

    Article  CAS  PubMed  Google Scholar 

  22. Mori Y, Cai K, Cheng Y, et al. A genome-wide search identifies epigenetic silencing of Somatostatin, Tachykinin-1, and 5 other genes in colon cancer. Gastroenterology. 2006;131:797–808.

    Article  CAS  PubMed  Google Scholar 

  23. Peng DF, Kanai Y, Sawada M, et al. DNA methylation of multi tumor-related genes in association with overexpression of DNA methytransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis. 2006;27:1160–1168.

    Article  CAS  PubMed  Google Scholar 

  24. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001;61:7025–7029.

    CAS  PubMed  Google Scholar 

  25. Primeau M, Gagnon J, Momparler RL. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer. 2003;103:177–184.

    Article  CAS  PubMed  Google Scholar 

  26. Xiong Y, Dowdy SC, Podratz KC, et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res. 2005;65:2684–2689.

    Article  CAS  PubMed  Google Scholar 

  27. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000;60:1835–1839.

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China

    Ling Zhang, Jun Gao, Zhaoshen Li & Yanfang Gong

Authors
  1. Ling Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhaoshen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yanfang Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhaoshen Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, L., Gao, J., Li, Z. et al. Neuronal pentraxin II (NPTX2) Is Frequently Down-Regulated by Promoter Hypermethylation in Pancreatic Cancers. Dig Dis Sci 57, 2608–2614 (2012). https://doi.org/10.1007/s10620-012-2202-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2202-8

Keywords

Search

Navigation